

Maciej Polak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7798950/publications.pdf>

Version: 2024-02-01

35
papers

390
citations

840119

11
h-index

794141

19
g-index

35
all docs

35
docs citations

35
times ranked

799
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, awareness, treatment and control of hypertension in the adult Polish population â€“ Multi-center National Population Health Examination Surveys â€“ WOBASZ studies. Archives of Medical Science, 2018, 14, 951-961.	0.4	44
2	Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland. Archives of Medical Science, 2016, 4, 687-696.	0.4	37
3	Perioperative restrictive versus goal-directed fluid therapy for adults undergoing major non-cardiac surgery. The Cochrane Library, 2019, 12, CD012767.	1.5	36
4	Association between tea and coffee consumption and prevalence of metabolic syndrome in Poland â€“ results from the WOBASZ II study (2013â€“2014). International Journal of Food Sciences and Nutrition, 2018, 69, 358-368.	1.3	33
5	Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. PLoS Medicine, 2018, 15, e1002505.	3.9	31
6	Relationship between mechanical factors and pelvic tilt in adults with and without low back pain. Journal of Back and Musculoskeletal Rehabilitation, 2017, 30, 699-705.	0.4	24
7	Prognostic Factors for Nonasphyxia-Related Cardiac Arrest Patients Undergoing Extracorporeal Rewarming - HELP Registry Study. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 365-371.	0.6	24
8	Area-Based Socio-Economic Inequalities in Mortality from Lung Cancer and Respiratory Diseases. International Journal of Environmental Research and Public Health, 2019, 16, 1791.	1.2	20
9	Socioeconomic status and pulmonary function, transition from childhood to adulthood: cross-sectional results from the polish part of the HAPIEE study. BMJ Open, 2019, 9, e022638.	0.8	18
10	Faster fibrin clot degradation characterizes patients with central pulmonary embolism at a low risk of recurrent peripheral embolism. Scientific Reports, 2019, 9, 72.	1.6	15
11	Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties. Journal of Thrombosis and Thrombolysis, 2019, 47, 8-15.	1.0	14
12	Relationship between past myocardial infarction, periodontal disease and Porphyromonas gingivalis serum antibodies: A case-control study. Cardiology Journal, 2018, 25, 386-392.	0.5	10
13	Cardiovascular disease (CVD) risk factors in KrakÃ³w and in the whole Poland adult population. Results from the WOBASZ study and Polish arm of the HAPIEE project. Przegląd Epidemiologiczny, 2015, 69, 79-86, 175-80.	0.4	9
14	Factors Influencing the Concentration of Exhaled Nitric Oxide (FeNO) in School Children Aged 8â€“9-Years-Old in Krakow, with High FeNO Values â‰¥ 20 ppb. Medicina (Lithuania), 2022, 58, 146.	0.8	8
15	Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein. Vascular Pharmacology, 2022, 144, 106977.	1.0	8
16	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. PLoS ONE, 2020, 15, e0234911.	1.1	7
17	Study on changing patterns of reproductive behaviours due to maternal features and place of residence in Poland during 1995â€“2014. Annals of Agricultural and Environmental Medicine, 2018, 25, 137-144.	0.5	6
18	Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study. Cardiovascular Diabetology, 2021, 20, 47.	2.7	6

#	ARTICLE	IF	CITATIONS
19	Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. <i>Targeted Oncology</i> , 2021, 16, 415-424.	1.7	6
20	Oxidative/Antioxidative Status in Patients after Myocardial Infarction and in Those without Cardiovascular Event Depending on Anthropometric Factors Defining Body Weight. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4077.	1.2	4
21	Associations between Pharmacotherapy for Cardiovascular Diseases and Periodontitis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 770.	1.2	4
22	Relationship Between Air Pollution and the Concentration of Nitric Oxide in the Exhaled Air (FeNO) in 8-9-Year-Old School Children in Krakow. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6690.	1.2	4
23	Relationship between Dietary Macronutrients Intake and the ATHLOS Healthy Ageing Scale: Results from the Polish Arm of the HAPIEE Study. <i>Nutrients</i> , 2022, 14, 2454.	1.7	4
24	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	4
25	A Multidimensional Questionnaire to Measure Career Satisfaction of Physicians: Validation of the Polish Version of the 4CornerSAT. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1033.	1.2	3
26	Socioeconomic Status, Health Behaviours and Oral Health in Adult Urban Population of Krakow. <i>Dental and Medical Problems</i> , 2016, 53, 66-77.	0.7	3
27	Association between central and peripheral blood pressure and periodontal disease in patients with a history of myocardial infarction. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 41-47.	0.3	3
28	Relationship between Serum Kallistatin and Afamin and Anthropometric Factors Associated with Obesity and of Being Overweight in Patients after Myocardial Infarction and without Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2021, 10, 5792.	1.0	3
29	Predictors of Higher Quality of Systematic Reviews Addressing Nutrition and Cancer Prevention. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 506.	1.2	2
30	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. , 2020, 15, e0234911.		0
31	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. , 2020, 15, e0234911.		0
32	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. , 2020, 15, e0234911.		0
33	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. , 2020, 15, e0234911.		0
34	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. , 2020, 15, e0234911.		0
35	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. , 2020, 15, e0234911.		0